Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...
Summit Therapeutics and Akeso published results for the Phase III HARMONi-2 trial, which tested ivonescimab, a bispecific ...
ThePrint on MSN4d
This experimental lung cancer drug outperforms blockbuster medicine Keytruda. But there’s a catchIn head-to-head clinical trial, Chinese firm Akeso’s ivonescimab beat top-selling drug pembrolizumab sold as Keytruda by ...
Summit Therapeutics acquired rights to ivonescimab outside of China and Australia. With Keytruda sales up around $25 billion ...
Japan’s MHLF approves Padcev with Keytruda for first-line treatment of radically unresectable urothelial carcinoma: Tokyo Wednesday, September 25, 2024, 11:00 Hrs [IST] Astellas ...
Zacks Small Cap Research on MSN12h
AEMD: Positive Takeaways from Life Science Investor Forum PresentationAEMD READ THE FULL AEMD RESEARCH REPORT AEMD basket oncology trial, patient enrollment process We participated in a ...
A candidate that Instil Bio in-licensed this August is similar to a candidate that recently outperformed the world's ...
Akeso and Summit Therapeutics' ivonescimab showed strong efficacy against Merck's Keytruda in a phase 3 trial in China. The ...
Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...
BT-001 is a multifunctional oncolytic virus encoding for an anti-CTLA4 antibody and the cytokine GM-CSF ... BT-001 induced tumor shrinkage in 2 of 6 injected lesions.In combination with KEYTRUDA® ...
The European Society for Medical Oncology’s annual meeting this week featured the hottest emergent areas of cancer ...
Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback